Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a specialty pharma company with...
Pharmaceutical
Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled...
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review...
Transpire Bio Achieves Important Corporate Milestone with Completion of First Human Subject Study in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program
WESTON, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines,...
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate...
Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion’s €7...
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD),...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis...
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical...
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed...
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed’s Phase IIb Palliative Care Trial
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin ExtractVancouver,...
Dubai’s thriving co-working sector drives D/Quarters to double space at Dubai Science Park
Demand from new pharmaceutical and existing customers reaffirms the newly expanded D/Quarters' vital role in nurturing innovation at Dubai Science ParkDUBAI,...
Great Bay Bio Completes First Close of Series B Financing
HONG KONG, Dec. 17, 2024 /PRNewswire/ -- Great Bay Bio (GBB) is thrilled to announce the successful first close of its...
Axtria Unveils New US and Global Incentive Compensation Benchmarking Studies: Insights That Drive Life Sciences Success
Key Trends, Metrics, and Best Practices Unveiled to Optimize Incentive Strategies and Drive Performance in Life Sciences BERKELEY HEIGHTS, N.J.,...
datma Introduces New Pathology Data Labeling System for its Flagship Federated Real World Data Platform, Expanding the Use of Pathology Imaging for Precision Medicine Drug Discovery and Development
New datma Patent Simplifies the Integration of Pathology Data into datma.FED Platform BEAVERTON, Ore., Dec. 16, 2024 /PRNewswire/ -- datma, a...
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE)...
Neural Therapeutics Announces Changes to Board of Directors and Completion of Debt Settlement
Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company...
Promise Bio Emerges from Stealth with $8.3M Seed Investment to Transform Precision Medicine for Immune-Mediated Diseases
Company unveils breakthrough platform that integrates epiproteomics and AI to identify predictive biomarkers for personalized treatments and support drug development...